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Background: Sizwe Tropical Diseases Hospital is the only specialized Hospital for the management of
multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB cases in Gauteng Province. In South
Africa, there is a mismatch between numbers of individuals with a laboratory diagnosis of drug-resistant
tuberculosis (TB) and those being referred for the initiation of specialist treatment. We determined reasons for
non-referral of MDR-TB and XDR-TB cases.
Methods: We conducted a descriptive questionnaire-based study amongst provincial primary health care
facilities (PHC) and hospitals providing routine care for (drug-susceptible) TB, regarding specialist care referral
of patients whose TB culture and susceptibility testing confirmed MDR-TB or XDR-TB diagnoses in the first
half of 2008.
Results: In total 148 cases were analyzed; 144/148 (97%) had MDR-TB and 4/148 (3%) had XDR-TB. The main
reason for non-referral to specialist care was loss to follow up, for patients diagnosed in-hospital (74/97; 76%)
as well as in PHCs (11/21; 52%). Nineteen per cent (18/97) of patients diagnosed in hospital versus 33% (7/21)
of patients diagnosed in PHCs deceased before referral.
Conclusions: A significant problem in the fight to control DR-TB is follow-up after diagnosis with a delay in
patient tracing. TB Focal Points in hospital need to be strengthened in order to improve on patient follow-up
and care, and tracer teams should assist with community follow up.
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reproduction in any medium, provided the orand only about 1% of these cases were on treatment
regimens based on WHO recommended standards
[1]. In 2010, extensively drug-resistant (XDR)-TB was
reported in 58 countries throughout all regions of
the world. Due to the emergence of MDR-TB, the
WHO developed a directly observed therapy short-
course (DOTS) Plus strategy in 2000 [2]. This strat-
egy aims at ensuring correct identification and proper
management of MDR-TB patients. DOTS-Plus treat-
ment of MDR-TB cases has been proven to be highly
cost effective in certain areas [3,4].
Treatment delays have been attributed to various
factors, such as living far from the health care facility,
feeling a high degree of stigma, seeking initial care attd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more than one health care encounter before diagno-
sis. However, health providers’ and health systems’ in-
herent delays have been found to account for the
major part of the total delay [5,6]. The delay in the
diagnosis and treatment of MDR-TB can result in
patients developing persistent disease, progressive par-
enchymal destruction, higher bacillary loads, continu-
ing transmission and increased mortality. In most
public health settings there is lack of adequate and
appropriate infection-control measures and, together
with high human immune-deficiency virus (HIV) co-
infection rates in certain settings [7], this represents a
public health emergency, calling for earlier detection
and treatment of drug resistant TB [8].
South Africa currently ranks fourth amongst countries
with a high absolute number of MDR-TB cases, with an
estimated number of 13.000 (6.7% of retreatment and
1.8% of new TB cases) [1,5,6], and with a high rate of
HIV co-infection [7]. Comprehensive programmatic
management of patients with MDR-TB became national
South African policy in 2000 and was implemented
through provincial MDR-TB referral centres [9]. The
most advantageous strategy for MDR-TB patients capi-
talizes on early diagnosis of MDR-TB [10].
Gauteng Province with only 1.4% of South Africa’s
land surface is highly urbanized and has an estimated
population of between 8.8 and 9.5 million people. As
South Africa’s economic hub, Gauteng attracts people
from all across the country as well as the Southern
African region who come in search of employment
opportunities. The province is divided into six health
care districts with a number of hospitals and PHCs.
Within the larger hospitals, TB Focal Points were
established in most of the major hospitals. TB Focal
Points are centres dedicated to effective diagnosis, inves-
tigation, and treatment of TB and simultaneous investi-
gation for HIV co-infection. Usually jointly staffed by
doctors and PHC nurses, they assist in the diagnosis and
referral of drug resistant TB. If patients are diagnosed
with MDR- or XDR-TB, they are transferred for treat-
ment to Sizwe Tropical Diseases Hospital (SH), a 268-
bed specialized treatment centre for MDR- and XDR-TB
patients.
According to the 2008 South African guidelines on
management of MDR-TB, MDR-TB patients were admit-
ted for at least the first six months or until they had
produced two consecutive monthly culture-negative
sputa [11].
Prior to this study, SH estimated that 30-40% of
culture-confirmed patients were unaccounted for in
terms of treatment in Gauteng province.
The objectives of the study were to determine the num-
ber of culture and DST confirmed MDR- and XDR-TBcases in Gauteng that were not referred for specialist
treatment at SH during the study period, and to identify
reasons for this, with a focus on the functioning of health
care facility follow up systems.
Methods
Study design
A descriptive study was conducted from October 2008
to December 2008, comprising retrospective review of
patient records and laboratory data of all patients, whose
TB culture and susceptibility testing confirmed MDR- or
XDR-TB in the first half of 2008. Patients who were
suspected of having DR-TB at any of the health care
facilities throughout Gauteng province had their drug
susceptibility testing (DST) performed at the South
African National TB Reference Laboratory (NTBRL).
The DST results were sent back from the NTBRL to
the requesting health care facilities; drug-resistant re-
sults indicating to the facilities the eligibility of the
patients for being referred to SH for specialist treatment.
A case was defined as a new laboratory-confirmed
MDR- or XDR-TB patient who was not on treatment
for DR-TB, identified from the NTBRL database between
1 January 2008 and 30 June 2008. Using a convenience
sample, 40 health care facilities (hospitals and PHCs)
in four of the six districts of Gauteng province were
identified. Health care professionals at these institutions
were interviewed using semi-structured questionnaires
with regard to their patient referral procedures in general;
and on those patients whose referral failed in particular.
Data collection
Data of all patients who were admitted to SH for initi-
ation of DR-TB treatment between January and June
2008 were compared to NTBRL data of all the
laboratory-confirmed MDR- and XDR-TB cases, which
were diagnosed from 1 January 2008 to 30 June 2008.
Patients who were positive for MDR- or XDR-TB but
did not appear on the SH admission record sheet were
traced back to referral facilities. Information on referral
health care facility and date of laboratory test confirm-
ation was collected from the NTBRL data. A site man-
ager or a professional nurse at each identified facility
was interviewed using a semi-structured questionnaire
after signing a consent form, with regard to (part A)
specificities of site management of newly identified
MDR- and XDR-TB cases, and (part B) on those patients
not subsequently appearing at SH.
Statistical analysis
From the various health facilities, data on health care
workers’ responses to the questionnaires was categorized
and reported as percentages and absolute frequencies.
Continuous variables were reported in median and
Table 2 Factors that affect implementation of MDR-TB
guidelines in referring facilities
Factor Hospital n/N (%) Clinic n/N (%)
Staff not aware of MDR-TB
guidelines
7/11 (64%) 24/29 (83%)
Staff do not know SH telephone
number
4/11 (36%) 11/29 (38%)
Patient follow up perceived
as difficult
11/11 (100%) 29/29 (100%)
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Ethical approval
The study was approved by the ethics committees of the
University of the Witwatersrand, Johannesburg, and the
University of Pretoria.
Results
Four out of six districts (Johannesburg, Tshwane,
Sedibeng, Metsweding) contributed data. A total of 148
cases in 40 facilities (29 PHC and 11 hospitals) were
analyzed. One hundred and forty-four cases (97%) were
MDR-TB and 4 (3%) were XDR-TB. The median age
in files specifying age (95/148) was 35 years (range:
10–82 years) and amongst those data sets specifying
patient sex (121/148), there were more females (59%;
72/121) than males.
Reasons for failure of referral to specialist care of
MDR- and XDR-TB patients are shown in Table 1. One
hundred and eighteen cases (80%) of the total number of
cases identified in the NRTBL were not seen back for
results in the diagnosis-initiating health care facilities,
and could therefore not been referred for treatment at
SH. The most important reason for non-referral to spe-
cialist care was loss to follow up, for patients diagnosed
in-hospital (74/97; 76%) as well as in PHCs (11/21; 52%).
There was a high mortality during the interval between
diagnosis and referral; of the patients diagnosed in hos-
pital, 19% (18/97) deceased before referral versus 33%
(7/21) of patients diagnosed in PHCs, resulting in an
overall mortality of 21% (25/118).
Looking into obstacles to refer patients correctly; one
major problem was that of health care facility staff
interviewed, 24/29 in PHC (86%) and 7/11 in hospitals
(64%) were not aware of the national MDR-TB guide-
lines (Table 2). When comparing methods of results de-
livery from the laboratory to the clinical care personnel
in PHC and hospitals (Table 3), about 96% (28/29) of
PHC used a courier service, whilst 90% (10/11) of hospi-
tals used fax services. The majority of PHCs (18/29;Table 1 Reasons for cases not being seen for results in
facilities, Gauteng, Jan 2008 - June 2008
Reason Hospital n (%) Clinic n (%) Total count
Loss to follow up1 74 (76%) 11 (52%) 85 (72%)
Deceased 18 (19%) 7 (33%) 25 (21%)
Did not come for results2 4 (4%) 1 (5%) 5 (4%)
Relocated 1 (1%) 2 (10%) 3 (3%)
Total 97(100%) 21 (100%) 118 (100%)
1Tracing of patient by health facility worker unsuccessful.
2Patients who were traced e.g. by phone (and had appointments) who did fail
to present at the health facility for follow-up.62%) arrange for home visits to inform the patients of
the outcome of their results whilst most hospitals (7/11;
63%) use phone calls. Most PHC (16/29; 55%) routinely
send patients with referral letters and an escort when re-
ferring them to SH for treatment, whilst only 4/11 hos-
pitals (36%) did the same. After transfer, only 1/29 PHC
and none of the hospitals routinely follows up on
referred cases to ensure that the patient has reached SH
(Table 3).
Discussion
In this study, loss to follow up was the most important
reason for failure of referral of MDR- and XDR-TB
patients to specialist care, both for hospital and PHC di-
agnosed cases. A considerable number of patients de-
ceased in the interval between diagnosis and referral,
highlighting the importance of a stringent, timely and
effective referral system for this extremely vulnerable pa-
tient group. Most operational problems mentioned, such
as the lack of knowledge of MDR-TB guidelines or com-
munication procedures regarding referral, seem to be
rectifiable with a reasonable amount of effort and cost.
At the time this study was carried out, referral of
newly diagnosed TB patients with multi- or higher de-
grees of drug resistance to specialized units for treat-
ment until repeated culture negativity was managed
according to the by then actual national guidelines in
South Africa. In the light of non-feasibility in many parts
of the country and assumedly in other settings world-
wide, with an evident mismatch between beds avail-
able and patient numbers, guidelines are now moving
towards favoring outpatient care. Nevertheless, an
outpatient-based care system will require a sound
public health system to capitalize on [11,12].
In this study, absolute numbers of MDR- and XDR-TB
patients who were not started on appropriate treatment
(because they were not referred) were highest for those
diagnosed in hospitals (compared to those diagnosed at
clinics). This is in part due to the fact that even though
the laboratories in these hospitals have documentation
of the sputum culture results, the personnel at the TB
focal points did not have any documentation of having
seen these cases after they were discharged. The cases
are discharged and not routinely provided with a date to
Table 3 Referral system of cases in clinics and hospitals
Hospital n/N (%) Clinic n/N (%)
Mode of results delivery to facility Fax 10/11 (91%) Fax 1/29 (3%)
Method used by facility to inform patients about results Home visits 4/11 (36%) Home visits 18/29 (62%)
Method used by facility to inform SH Phone 7/11 (64%) Phone 13/29 (45%)
Method used by facility to send patient to SH Referral letter and escort 4/11 (36%) Referral letter and escort 16/29 (55%)
Follow up of patients by facility after transfer to SH Never 4/11 (36%) Never 4/29 (14%)
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died before results could be communicated back to
them. In Africa, death and default rates due to TB are
high and they are linked to high rates of HIV co-
infection and weak health care services [10]. Immune
status, the application of appropriate drug treatment,
culturing of mycobacteria within 30 days and age are
significant factors associated with survival in MDR-TB
cases [13].
The hospitals have the convenience of receiving their
results via fax since the laboratory is located on the hos-
pital premises. In the clinics, a courier service is utilized
which delivers the results daily. The clinics task is to en-
sure that cases are informed of their laboratory results
by sending DOT supporters/community health workers
to do home visits and providing an escort who will make
sure that they reach the referral hospital.
One possible explanation for referral problems occur-
ring on staff level is that there may be a considerable
level of staff rotating through different health center ra-
ther than “TB staff” being permanently in their positions;
to what extent this is a contributing factor would remain
to be elucidated.
Our study demonstrates that there is room for im-
provement at the level of the referring health care facil-
ities. Clear allocation of responsibilities and training of
staff identified to carry out this important task is para-
mount for sustainable improvement.
Our study has various limitations. The sample size was
limited and data were missing in some of the patient re-
cords for sex, age, occupation and type of residence. The
role of laboratory delays in terms of time lapse between
a positive result and its communication back to the
specimen-submitting unit was not studied because there
were no data available on the date of sputum arrival in
the healthcare facility.
Conclusions
Dysfunctional health systems will result in new anti-TB
drugs following the same path to resistance that the
current drugs have taken [14]. For efficient treatment,
patients have to be identified, traced and diagnosed be-
fore they can be referred for treatment, no matter
whether treatment will be in- or outpatient based.Our findings suggest that the main reason for non-
referral of MDR- and XDR-TB to specialized treatment
facilities is loss to follow up, mainly due to a lack of
well-functioning follow-up and referral systems in hospi-
tals and clinics diagnosing DR-TB. To tackle the deficits
in patient follow-up and care after diagnosis (as an im-
portant reason for the lack of continuation of care for
MDR- and XDR-TB patients), TB referral systems (capit-
alizing on the existing TB focal point system) need to be
strengthened.
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